{
    "clinical_study": {
        "@rank": "153166", 
        "arm_group": {
            "arm_group_label": "Transthoracic echocardiogram (ultrasound)", 
            "description": "Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of  standard clinical care, will be further evaluated for special parameters that may help to detect weakening."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research study is to evaluate the effects of the chemotherapeutic drug,\n      Trastuzumab (Herceptin) on the heart.  Trastuzumab (Herceptin) is used to treat specific\n      types of breast cancer and is known to cause weakening of the heart. Unfortunately, little\n      is know as to why this this happens. The investigators want to identify any factors that may\n      lead to the early detection, treatment and prevention of the cardiotoxicity (heart problem)\n      associated with this drug."
        }, 
        "brief_title": "Strain Imaging in Breast Cancer Patients Receiving Trastuzumab", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Her 2 Positive Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "As a subject participating in this study the following information will be collected:\n      complete past medical history including age, height, and weight will be done with each\n      echocardiogram; blood pressure at clinic visits during treatment with trastuzumab, type of\n      cancer will be noted, type of chemotherapy, doses of chemotherapy, type and dose of\n      chemotherapy in the past, type and dose of radiation therapy received, names and doses of\n      cardiac medications, results of cardiac tests, results of lab tests, family history of heart\n      disease, and social history which will include risk factors for developing heart disease\n      including tobacco and alcohol use.  This information will be entered into a database for the\n      investigators to try and detect any factors that may lead to the cardiotoxicity (heart\n      problem) that may be caused by Trastuzumab (Herceptin).\n\n      Any transthoracic echocardiogram (heart ultrasound) ordered will be further evaluated for\n      special parameters that may help to detect weakening of the heart earlier than a normal\n      ultrasound.  An echocardiogram (heart ultrasound) is when a probe is placed on the chest and\n      pictures are taken using sound waves and a special camera."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age greater than 18 years\n\n          -  Her 2 positive breast cancer.\n\n          -  Patients who are currently receiving Trastuzumab (Herceptin).\n\n          -  Patients who received Trastuzumab (Herceptin) after the formation of the UFHealth\n             Medical Plaza pharmacy database was initiated.\n\n        Exclusion Criteria:\n\n          -  Age less than 18 years\n\n          -  Patients who have not received Trastuzumab (Herceptin).\n\n          -  Patients who received Trastuzumab prior to the formation of the UFHealth Medical\n             Plaza pharmacy database."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Women or men recieveing Trastuzumab (Herceptin) for HER2 positive breast cancer."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080390", 
            "org_study_id": "szady2014"
        }, 
        "intervention": {
            "arm_group_label": "Transthoracic echocardiogram (ultrasound)", 
            "description": "Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.", 
            "intervention_name": "Transthoracic echocardiogram (ultrasound)", 
            "intervention_type": "Procedure", 
            "other_name": "Transthoracic echocardiogram"
        }, 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Her 2 Positive Breast Cancer", 
            "Trastuzumab", 
            "Herceptin", 
            "Heart Failure", 
            "Echocardiography"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "leach@medicine.ufl.edu", 
                "last_name": "Dana D Leach, DNP-ARNP", 
                "phone": "352-273-8933"
            }, 
            "facility": {
                "address": {
                    "city": "Gainesville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32610"
                }, 
                "name": "Univerisity of Florida"
            }, 
            "investigator": [
                {
                    "last_name": "Anita D Szady, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Karen Daily, DO", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Petersen, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Strain Imaging in Breast Cancer Patients Receiving Trastuzumab", 
        "overall_contact": {
            "last_name": "Dana D Leach, DNP-ARNP-BC", 
            "phone": "(352)273-8933"
        }, 
        "overall_official": {
            "affiliation": "University of Florida", 
            "last_name": "Anita D Szady, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Each transthoracic echocardiogram obtained during the patient's treatment will be assessed for longitudinal strain.", 
                "measure": "Longitudinal Strain", 
                "safety_issue": "No", 
                "time_frame": "Change in baseline longitudinal strain from beginning of study to end of study. Patients will be followed for a minimum of 1 year."
            }, 
            {
                "description": "Left ventricular ejection fraction from all clinically indicated transthoracic echocardiograms will be compared from baseline through the end of the study.", 
                "measure": "Left Ventricular Ejection Fraction", 
                "safety_issue": "No", 
                "time_frame": "Change in ejection fraction from baseline to end of study. Patients will be followed for a minimum of 1 year."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080390"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinically evident congestive heart failure(symptoms of fluid overload such as shortness of breath, dyspnea on exertion, orthopnea or paroxysmal nocturnal dyspnea or physical findings of congestive heart failure such as jugular venous distension, rales on pulmonary exam, lower extremity edema).", 
                "measure": "Clinically evident congestive heart failure", 
                "safety_issue": "No", 
                "time_frame": "From baseline to end of study. Patients will be followed for a minimum of 1 year."
            }, 
            {
                "description": "The type and dose of all cardiac medications will be followed from baseline to end of study.", 
                "measure": "Cardiac medication use", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of study. Patients will be follwed for a minimum of 1 year."
            }
        ], 
        "source": "University of Florida", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}